Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma-Reference-Cited by-同舟云学术

Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma

Published:2024-06-20 Issue:1 Volume:15 Page:408-417
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kitajima Kazuhiro¹,Kuribayashi Kozo²,Minami Toshiyuki²,Yokoyama Hiroyuki¹,Nakamura Akifumi³,Hashimoto Masaki³,Kijima Takashi²,Hasegawa Seiki³,Kaida Hayato⁴,Yamakado Koichiro¹

Affiliation:

1. Department of Radiology, Hyogo Medical University, Nishinomiya, Hyogo, Japan

2. Division of Respiratory Medicine, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan

3. Department of Thoracic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan

4. Department of Radiology, Kindai University Faculty of Medicine, Osaka, Japan

Publisher

Impact Journals, LLC

Reference16 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Paoletti;J Clin Oncol,2003

2. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial;Gervais;Lancet,2016

3. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial;Janthur;Ann Oncol,2020

4. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy;Allison;Cancer Discov,2018

5. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial;Urban;Lancet Oncol,2019